{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:43:00Z","timestamp":1789422180065,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023280","name":"Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128436","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:45:41Z","timestamp":1773891941000},"page":"128436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies"],"prefix":"10.1016","volume":"79","author":[{"given":"Fred","family":"de Looze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"van Boxmeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"de Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Piedrahita","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128436_bb0005","unstructured":"WHO. Influenza (seasonal). 2025 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal). [October 2025]."},{"key":"10.1016\/j.vaccine.2026.128436_bb0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s12325-023-02432-1","article-title":"High clinical burden of influenza disease in adults aged \u226565 years: can we do better? A systematic literature review","volume":"40","author":"Langer","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2026.128436_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2257048","article-title":"The burden of influenza and the role of influenza vaccination in adults aged 50-64 years: a summary of available evidence","volume":"19","author":"Marchi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128436_bb0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.chom.2019.05.012","article-title":"A tale of two mutations: beginning to understand the problems with egg-based influenza vaccines?","volume":"25","author":"Subbarao","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128436_bb0025","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.3390\/ijerph17155423","article-title":"Retrospective assessment of the antigenic similarity of egg-propagated and cell culture-propagated reference influenza viruses as compared with circulating viruses across influenza seasons 2002-2003 to 2017-2018","volume":"17","author":"Rajaram","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2026.128436_bb0030","article-title":"Seasonal influenza vaccination: overcoming immunosenescence with enhanced vaccines","volume":"24","author":"Boivin","year":"2025","journal-title":"Vaccine: X"},{"key":"10.1016\/j.vaccine.2026.128436_bb0035","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1093\/cid\/ciaa1944","volume":"73","author":"Boikos","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0040","article-title":"Review of analyses estimating relative vaccine effectiveness of cell-based quadrivalent influenza vaccine in three consecutive US influenza seasons","volume":"10","author":"Boikos","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128436_bb0045","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1093\/cid\/ciaa371","article-title":"Relative effectiveness of the cell-cultured Quadrivalent influenza vaccine compared to standard, egg-derived Quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018","volume":"71","author":"Boikos","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0050","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1016\/j.vaccine.2020.07.023","article-title":"A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season","volume":"38","author":"Divino","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0055","article-title":"A real-world clinical and economic analysis of cell-derived Quadrivalent influenza vaccine compared to standard egg-derived Quadrivalent influenza vaccines during the 2019-2020 influenza season in the United States. Open forum","volume":"9","author":"Divino","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128436_bb0060","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/INF.0000000000003620","article-title":"Relative effectiveness of cell-based versus egg-based quadrivalent influenza vaccines in children and adolescents in the United States during the 2019-2020 influenza season","volume":"41","author":"Imran","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128436_bb0065","article-title":"Relative effectiveness of cell-based versus egg-based quadrivalent influenza vaccines in adults during the 2019-2020 influenza season in the United States","volume":"9","author":"Imran","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020080","article-title":"Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. standard-dose egg-based quadrivalent influenza vaccines during the 2018\u201319 influenza season in the United States","volume":"9","author":"Krishnarajah","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128436_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.824","article-title":"Relative vaccine effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza in the United States 2022\u201323 influenza season","volume":"12","author":"Stein","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae175","article-title":"Relative vaccine effectiveness of cell- vs egg-based quadrivalent influenza vaccine against test-confirmed influenza over 3 seasons between 2017 and 2020 in the United States","volume":"11","author":"Stein","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0085","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s40121-025-01230-2","article-title":"Superior effectiveness and estimated public health impact of cell- versus egg-based influenza vaccines in children and adults during the US 2023-2024 season","volume":"14","author":"Stein","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128436_bb0090","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","article-title":"Understanding immunosenescence and its impact on vaccination of older adults","volume":"38","author":"Allen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2026.128436_bb0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"CA","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128436_bb0105","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2026.128436_bb0110","series-title":"Immunopotentiators in Modern Vaccines (Second Edition)","first-page":"249","article-title":"Chapter 13 - MF59: A Safe and Potent Adjuvant for Human Use","author":"Kommareddy","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128436_bb0115","author":"McCarthy"},{"key":"10.1016\/j.vaccine.2026.128436_bb0120","author":"TGA"},{"key":"10.1016\/j.vaccine.2026.128436_bb0125","author":"Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2026.128436_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126791","article-title":"A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older","volume":"51","author":"Essink","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0135","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128436_bb0140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","article-title":"Cell culture-based influenza vaccines: a necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128436_bb0145","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.vaccine.2019.10.058","article-title":"A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults\u00a0\u2265\u00a065 years of age","volume":"38","author":"Otten","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0150","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128436_bb0155","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jix478","article-title":"Randomized comparison of immunogenicity and safety of Quadrivalent recombinant versus inactivated influenza vaccine in healthy adults 18-49 years of age","volume":"216","author":"Dunkle","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/595842","article-title":"Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50\u201364 years","volume":"48","author":"Nichol","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128436_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2051013615595595","article-title":"Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults","volume":"3","author":"Cox","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2026.128436_bb0175","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1080\/21645515.2015.1064570","article-title":"A 2013\/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--assessing the immunogenicity and safety in an open label, uncontrolled study","volume":"11","author":"Roggelin","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128436_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1285475","article-title":"Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China","volume":"13","author":"Mo","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128436_bb0185","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.vaccine.2012.01.015","article-title":"The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines","volume":"30","author":"McElhaney","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101331","article-title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis","volume":"46","author":"Minozzi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128436_bb0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/vaccines11010052","article-title":"Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness","volume":"11","author":"Rockman","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128436_bb0200","article-title":"Enhancing the response to avian influenza in the US and globally","volume":"46","author":"Bartlett","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2026.128436_bb0205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14760584.2025.2515597","article-title":"Maintaining the value of influenza vaccination \u2013 the shift from quadrivalent to trivalent vaccines: an expert review","volume":"24","author":"Fisman","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128436_bb0210","author":"European Medicines Agency"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:52:34Z","timestamp":1781308354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"alternative-id":["S0264410X26002446"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128436","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128436"}}